“We’re gearing up for a busy and productive fall as we prepare for three of the bigger events in the veterinary marketplace, after a year where all in-person events were cancelled or held virtually. We expect MiQLab’s in-person presence will have significant impact in the veterinary marketplace and look forward to demonstrating how vet practices will greatly benefit from in-clinic PCR diagnostics. Our attendance allows us to take a full-on approach with building brand awareness, exciting potential buyers, and improving our market reach through our revamped marketing and sales strategies.”

https://ca.finance.yahoo.com/news/lexagene-miqlab-system-featured-three-114500638.html

 
 

Read more on this topiBEVERLY, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army’s Combat Capabilities Development Command (DEVCOM) (https://www.cbc.devcom.army.mil/).This CRADA aims to foster innovative biothreat defense capability development, which is part of DEVCOM’s current technology priorities. LexaGene will work with the United States Army to demonstrate the capabilities of the MiQLabTM, LexaGene’s flagship pathogen detection system.

SEPTEMBER 16, 2021 LEXAGENE is pleased to announce it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army’s Combat Capabilities Development Command (DEVCOM) 

https://ca.finance.yahoo.com/news/lexagene-enters-cooperative-research-development-114500038.html